Could Illumina Be a Millionaire-Maker Stock?
Like peers in the life sciences industry, Illumina (NASDAQ: ILMN) hasn't been immune to the coronavirus outbreak. Shares of the genome sequencing giant fell as much as 37% earlier this year as the outbreak led to a general market crash.
The crisis also hurt revenue: The maker of genome sequencing systems saw a slowdown in business as some customers temporarily closed labs, and as a result, delayed testing using Illumina's tools. Illumina isn't offering an outlook on the months ahead because the duration of the coronavirus crisis isn't clear.
Image source: Getty Images.
Source Fool.com
